<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1990">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135260</url>
  </required_header>
  <id_info>
    <org_study_id>VICC SUPP 2079</org_study_id>
    <nct_id>NCT05135260</nct_id>
  </id_info>
  <brief_title>Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic</brief_title>
  <official_title>The Effects of Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cody Stansel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the ability of virtual reality to function as a novel distraction&#xD;
      intervention and improve the experience of patients who are receiving chemotherapy in the&#xD;
      infusion clinic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      - To deploy and evaluate virtual reality as an intervention for stress, pain, and negative&#xD;
      affect&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      - To evaluate cyber sickness and patient satisfaction related to the virtual reality&#xD;
      treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive or negative effect of Virtual Reality therapy on improving the experience of participants receiving chemotherapy</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Measured by the Positive and Negative Affect Scale (0=minimum to 5=maximum). Consisting of a number of words that describe different feelings and emotions. Patients are instructed to indicate to what extent they currently feel each of the feelings or emotions. Afterwards, patient responses are scored to produce a numerical positive affect score and a negative affect score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the affect of Virtual Reality Therapy on improving stress</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Measured by stress level using the stress numerical rating</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the affect of Virtual Reality Therapy on improving pain</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Measured by pain level using the pain numerical score (scale 0 (none) to 10 (worst)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of cyber sickness (Virtual Reality Therapy Arm Only)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Measured with the Fast MS Scale (FMS), a verbal rating scale ranging from zero (no sickness at all) to 20 (frank sickness).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Virtual Reality Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will not watch videos, but will continue with their normal routine as if nothing has changed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual reality therapy</intervention_name>
    <description>Participants will watch a video allowing them to view nature, dinosaurs, animals, and human interactions in three dimensions during a session lasting 11 minutes.</description>
    <arm_group_label>Virtual Reality Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires will be completed regarding stress, pain and affect</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Virtual Reality Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Measure heart rate</intervention_name>
    <description>To be measured prior to starting treatment and halfway through the 11 minute Video</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Virtual Reality Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cyber sickness measurement</intervention_name>
    <description>To be measured using the fast motion sickness scale</description>
    <arm_group_label>Virtual Reality Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At or above the age of 18&#xD;
&#xD;
          -  English Speaking&#xD;
&#xD;
          -  Diagnosed with cancer&#xD;
&#xD;
          -  No previous history of seizures, losses of awareness, or other symptoms linked to an&#xD;
             epileptic condition&#xD;
&#xD;
          -  Not sensitive to motion sickness&#xD;
&#xD;
          -  Not currently experiencing any contagious conditions, infections, or diseases&#xD;
             (particularly of the eyes, skin, or scalp)&#xD;
&#xD;
          -  Does not use a device to regulate heart rate or rhythm (such as a pacemaker)&#xD;
&#xD;
          -  Not taking antiarrhythmic medications&#xD;
&#xD;
          -  Not actively receiving radiopharmaceutical therapy&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  To ensure that there is sufficient time to complete the virtual reality treatment,&#xD;
             patients who are scheduled for visits for periods of less than one hour will not be&#xD;
             included in this study. Additionally, patients must consent to participating in the&#xD;
             study on the day of the experience.&#xD;
&#xD;
          -  Patients who are asleep prior to consenting will not be asked to participate in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cody Stansel, MSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Cody Stansel, MSN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Cody Stansel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT05135260/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

